{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-127218","form_type":"8-K/A","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.597765+00:00","generated_at":"2026-05-30T00:25:53.222585+00:00","sec_items":["2.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TuHURA posts $15.7M net loss through Q3 2024; convertible debt rises to $24.4M","bullets":["Net loss of $15.7M for nine months ended Sep 30, 2024 vs $26.6M prior year (prior year included $16.2M IPR&D charge).","Operating loss of $12.0M vs $27.1M YoY; R&D spend up to $9.4M from $7.5M.","Cash position $19.6M at Sep 30, 2024, up from $3.7M year-end 2023 after $28.6M convertible note issuance.","Convertible notes payable net of discount total $24.4M; derivative liability of $2.9M recorded.","Stockholders' deficit worsened to $(2.8M) from $(1.6M); closed merger with Kintara on Oct 18, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-127218","json":"https://secwatch.observer/filing/0000950170-24-127218.json","markdown":"https://secwatch.observer/filing/0000950170-24-127218.md","text":"https://secwatch.observer/filing/0000950170-24-127218.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000095017024127218/0000950170-24-127218-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000095017024127218/hura-20241018.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:25:53.222585+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}